As­traZeneca names con­tro­ver­sial can­cer sci­en­tist José Basel­ga to a top R&D post in ma­jor shake­up

Just days af­ter Bahi­ja Jal­lal an­nounced her de­ci­sion to leave her post at the top of As­traZeneca’s big bi­o­log­ics sub­sidiary Med­Im­mune and take the helm at Im­muno­core, the phar­ma gi­ant is shak­ing up its R&D lead­er­ship and bring­ing in a con­tro­ver­sial new head of on­col­o­gy R&D.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.